Skip to main content
Stanford Peng, MD, Rheumatology, Seattle, WA, Swedish Cherry Hill Campus

StanfordLee-YuPengMDPhD

Rheumatology Seattle, WA

Lupus & Related, Rheumatoid Arthritis & Related, Scleroderma & Related, Spondyloarthropathy

Physician

Dr. Peng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Peng's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalFellowship, Rheumatology, 2002
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 1999
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemInternship, Internal Medicine, 1997 - 1998
  • Yale School of Medicine
    Yale School of MedicineClass of 1997

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2008 - 2026
  • CA State Medical License
    CA State Medical License 2005 - 2025
  • PA State Medical License
    PA State Medical License 1998 - 1999
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification HealthSentry EHR, Cerner Corporation, 2013
  • Fellow (FACP) American College of Physicians, 2012
  • Fellow American College of Rheumatology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • An Open Label Study of Alpn-101, a First-in-Class Dual CD28/ICOS Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (...
    Stanford L. Peng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • “Switch” Transmembrane Immunomodulatory Proteins (TIPs) Consisting of High-Affinity PD-1 Extracellular Domains (PD-1 vIgDs) and Costimulatory Intracellular Domains Pot... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Other

Press Mentions

  • Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (Pembrolizumab)
    Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (Pembrolizumab)June 30th, 2021
  • ASCO: Alpine Reports 61% 'Clinical Benefit' in Early Trial of CD28-Targeted Immuno-Oncology Drug
    ASCO: Alpine Reports 61% 'Clinical Benefit' in Early Trial of CD28-Targeted Immuno-Oncology DrugJune 7th, 2021

Grant Support

  • Molecular Mechanisms Of Autoreactive B Cell ActivationNational Institute Of Allergy And Infectious Diseases2005–2007
  • Molecular Mechanisms Of Autoreactive B Cell ActivationNational Institute Of Allergy And Infectious Diseases2004–2005
  • Forkhead Transcription Factors In T LymphocytesNational Institute Of Allergy And Infectious Diseases2004
  • The Function Of T-BET In T Helper Cell DevelopmentNational Institute Of Allergy And Infectious Diseases2002–2003
  • The Function Of T-BET In T Helper Cell DevelopmentNational Institute Of Allergy And Infectious Diseases2000–2001

Hospital Affiliations